ARCHIVES

Three researchers share Paul Marks Prize.

This article is from The Cancer Letter archive.

Vol. 31 No. 41 | November 11, 2005

Download PDF Visit The Full Archive

Related Articles

ImClone Offered C225 Deal To Seven Firms Prior To BMS

February 22, 2002

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

January 27, 2012

Drug Shortages Prompt Doctors, Societies to Consider Non-Profit Pharma Company

September 9, 2011

Patient Advocacy: FDA, NCI Developing Methods For Naming Survivors To Boards

February 7, 1997

Daily Vitamin E Supplements Can Lead to Increased PCa Risk

October 28, 2011

Deep Budget Cuts Poised to Kick in March 1; Hill Insiders See Little Hope for Deal

February 15, 2013